4530.T Живые сигналы | Максимизируйте прибыль с Getagraph.com

Live Chart Being Loaded With Signals

Commentary (26 апр. 2024 @ 09:15):

Stats
Объем за сегодня	224 600
Средний объем	169 435
Рыночная капитализация	286.23B
EPS	¥0 ( 2024-04-10 )
Дата следующего отчета о доходах	( ¥0 ) 2024-07-11
Last Dividend	¥42.50 ( 2023-08-30 )
Next Dividend	¥0 ( N/A )
P/E	20.49
ATR14	¥1.660 (0.04%)

Объем Корреляция

Длинно: 0.21 (neutral)

Кратко: 0.35 (neutral)

Signal:(75.566) Neutral

Hisamitsu Pharmaceutical Корреляция

10 Самые положительные корреляции

10 Самые отрицательные корреляции

Вы знали?

Корреляция - это статистический показатель, описывающий связь между двумя переменными. Он изменяется от -1 до 1, где -1 указывает на идеальную отрицательную корреляцию (при увеличении одной переменной другая уменьшается), 1 указывает на идеальную положительную корреляцию (при увеличении одной переменной другая увеличивается), а 0 указывает на отсутствие корреляции (между переменными нет связи).

Корреляцию можно использовать для анализа связи между любыми двумя переменными, не только акциями. Она широко используется в таких областях, как финансы, экономика, психология и т. д.

Hisamitsu Pharmaceutical Корреляция - Валюта/Сырье

-0.40
( neutral )

-0.32
( neutral )

-0.58
( weak negative )

0.32
( neutral )

-0.07
( neutral )

0.88
( strong )

Hisamitsu Pharmaceutical Финансовые показатели

Annual	2023
Выручка:	¥141.71B
Валовая прибыль:	¥78.97B (55.73 %)
EPS:	¥181.62

FY	2023
Выручка:	¥141.71B
Валовая прибыль:	¥78.97B (55.73 %)
EPS:	¥181.62

FY	2022
Выручка:	¥128.33B
Валовая прибыль:	¥72.70B (56.65 %)
EPS:	¥148.00

FY	2022
Выручка:	¥120.19B
Валовая прибыль:	¥70.07B (58.30 %)
EPS:	¥118.92

Financial Reports:

No articles found.

Hisamitsu Pharmaceutical Dividends

(Q3/22)	(Q4/22)	(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
¥0.250 (N/A)	¥0 (N/A)	¥0.250 (N/A)	¥0 (N/A)	¥42.50 (N/A)	¥0 (N/A)	¥0 (N/A)	¥0 (N/A)	¥0 (N/A)	¥0 (N/A)

Hisamitsu Pharmaceutical Dividend Information - Ex Dividend Knight

Dividend Sustainability Score: 10.00 - good (100.00%) | Divividend Growth Potential Score: 4.60 - Stable (8.07%)

Very Unsafe

High risk of being cut

Unsafe

Heightened risk of being cut

Borderline

Moderate risk of being cut

Safe

Unlikely to be cut

Very Safe

Very unlikely to be cut

Information

First Dividend	¥7.00	2001-02-23
Last Dividend	¥42.50	2023-08-30
Next Dividend	¥0	N/A
Payout Date	0000-00-00
Next Payout Date	N/A
# dividends	42	--
Total Paid Out	¥1 175.50	--
Avg. Dividend % Per Year	0.00%	--
Score	3.73	--
Div. Sustainability Score	10.00
Div.Growth Potential Score	4.60
Div. Directional Score	7.69	--

Next Divdend (Est)
(2024-09-05)

¥0 Estimate 7.25 %

Dividend Stability

0.29 Very Poor

Dividend Score

3.73

Pay Frequency

Semi-Annually

Yearly Payout

Year	Amount	Yield

Dividend Commentary

The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. In summary, the company provides a promising overall dividend outlook, balancing both sustainability and growth potential.

Top 10 dividend Companies for JPX

Symbol	Title	Last dividend	Frequency	Yearly Dividend
8174.T	Ex Dividend Knight	2023-09-28	Semi-Annually	0.00%
7552.T	Ex Dividend Knight	2023-09-28	Semi-Annually	0.00%
6762.T	Ex Dividend Knight	2023-09-28	Semi-Annually	0.00%
6101.T	Ex Dividend Knight	2023-09-28	Semi-Annually	0.00%
4812.T	Ex Dividend Knight	2023-12-28	Semi-Annually	0.00%
4026.T	Ex Dividend Knight	2023-10-30	Semi-Annually	0.00%
9982.T	Ex Dividend Knight	2024-02-28	Semi-Annually	0.00%
3242.T	Ex Dividend Knight	2023-12-28	Semi-Annually	0.00%
8966.T	Ex Dividend Knight	2023-11-29	Semi-Annually	0.00%
2267.T	Ex Dividend Knight	2023-09-28	Semi-Annually	0.00%

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	0.0986	1.500	8.03	10.00	[0 - 0.5]
returnOnAssetsTTM	0.0425	1.200	8.58	10.00	[0 - 0.3]
returnOnEquityTTM	0.0524	1.500	-0.529	-0.793	[0.1 - 1]
payoutRatioTTM	0	-1.000	0	0	[0 - 1]
currentRatioTTM	4.22	0.800	10.00	8.00	[1 - 3]
quickRatioTTM	3.66	0.800	10.00	8.00	[0.8 - 2.5]
cashRatioTTM	2.45	1.500	10.00	10.00	[0.2 - 2]
debtRatioTTM	0.00455	-1.500	9.92	-10.00	[0 - 0.6]
interestCoverageTTM	731.56	1.000	10.00	10.00	[3 - 30]
operatingCashFlowPerShareTTM	96.01	2.00	10.00	10.00	[0 - 30]
freeCashFlowPerShareTTM	96.01	2.00	10.00	10.00	[0 - 20]
debtEquityRatioTTM	0.00565	-1.500	9.98	-10.00	[0 - 2.5]
grossProfitMarginTTM	0.557	1.000	4.05	4.05	[0.2 - 0.8]
operatingProfitMarginTTM	0.0929	1.000	-0.142	-0.142	[0.1 - 0.6]
cashFlowToDebtRatioTTM	4.86	1.000	10.00	10.00	[0.2 - 2]
assetTurnoverTTM	0.431	0.800	-0.460	-0.368	[0.5 - 2]
Total Score				10.77

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	20.51	1.000	8.03	0	[1 - 100]
returnOnEquityTTM	0.0524	2.50	-0.340	-0.793	[0.1 - 1.5]
freeCashFlowPerShareTTM	96.01	2.00	10.00	10.00	[0 - 30]
dividendYielPercentageTTM	2.25	1.500	10.00	0	[0 - 0.4]
operatingCashFlowPerShareTTM	96.01	2.00	10.00	10.00	[0 - 30]
payoutRatioTTM	0	1.500	0	0	[0 - 1]
pegRatioTTM	0.903	1.500	7.31	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	0.0514	1.000	-1.216	0	[0.1 - 0.5]
Total Score				4.60

Hisamitsu Pharmaceutical

Hisamitsu Pharmaceutical Co., Inc. manufactures and sells pharmaceuticals, quasi-drugs, and medical devices in Japan. The company provides external pain relieving drugs under the SALONPAS, NOBINOBI, SALONSIP, AIR, SALONPAS, and FEITAS; and BUTENALOCK, a remedy for athlete's foot, as well as ALLEGRA FX, a sinus medication for allergies. It also manufactures and sells quasi-drugs and cosmetics; MOHRUS TAPE and MOHRUS PAP XR, transdermal analgesic anti-inflammatory drug; patches for female hormone, asthma treatment, and treatment for overactive bladders. In addition, the company manufactures and sells drugs under MOHRUS TAPE, MOHRUS PAP XR, FENTOS Tapes, NEOXY Tapes, Abstral, ALLESAGA Tapes, HARUROPI Tapes, and MENOAID Combipatch. Further, it provides HFT-290, a transdermal patch for cancer pain. The company sells its products in the United States and Asia. Hisamitsu Pharmaceutical Co., Inc. was founded in 1847 and is headquartered in Tosu, Japan.